SAHPRA Assures Public: No Substandard Cancer Drugs Found in South Africa
The South African Health Products Regulatory Authority (SAHPRA) has confirmed that all cancer medications currently registered and marketed in South Africa meet strict quality, safety, and efficacy standards. This assurance follows a recent Lancet Global Health study that highlighted the presence of substandard anti-cancer drugs in countries such as Ethiopia, Kenya, Malawi, and Cameroon. The study identified seven compromised medications, including cisplatin, oxaliplatin, methotrexate, doxorubicin, cyclophosphamide, ifosfamide, and leucovorin. However, […]